Purpura, Schoenlein-Henoch Clinical Trial
Official title:
The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura
The study aims to explore the therapeutic value and mechanism of Interleukin-2 on children with Henoch-schönlein purpura.
The investigators designed a single center, open-label, prospective study that routinely administered low-dose IL-2 therapy to monitor the improvement of clinical and laboratory parameters to explore its efficacy and to observe changes in immune cell subsets and cytokines.For all patients,rhIL-2(500,000 unit per square meter) infusions seven days;recurrent patients were applied again for 7 days;patients who were diagnosed HSPN were treated on a routine basis for 7 consecutive days, and then once every two week for 3months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01104428 -
Research on the Blood- Cooling - Toxin - Removing - Stasis - Dispersing Protocol Evaluation of Hench-schonlein Purpura
|
Phase 2 | |
| Active, not recruiting |
NCT00006055 -
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
|
N/A | |
| Completed |
NCT00425724 -
HSP-glomerulonephritis Trial: MP vs CyA
|
Phase 4 | |
| Recruiting |
NCT01610830 -
Identification of Biomarkers Predictive of Worse Prognosis in Henoch Schonlein Purpura
|
N/A |